MA50654A - Anticorps anti-pacap - Google Patents

Anticorps anti-pacap

Info

Publication number
MA50654A
MA50654A MA050654A MA50654A MA50654A MA 50654 A MA50654 A MA 50654A MA 050654 A MA050654 A MA 050654A MA 50654 A MA50654 A MA 50654A MA 50654 A MA50654 A MA 50654A
Authority
MA
Morocco
Prior art keywords
pacap antibodies
pacap
antibodies
Prior art date
Application number
MA050654A
Other languages
English (en)
French (fr)
Inventor
Catherine Brautigam Beidler
Michael Parvin Johnson
Chetankumar Natvarlal Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50654A publication Critical patent/MA50654A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050654A 2017-09-29 2018-09-20 Anticorps anti-pacap MA50654A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50654A true MA50654A (fr) 2020-08-05

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050654A MA50654A (fr) 2017-09-29 2018-09-20 Anticorps anti-pacap

Country Status (27)

Country Link
US (3) US10519225B2 (https=)
EP (1) EP3688035A1 (https=)
JP (2) JP6952888B2 (https=)
KR (1) KR102453573B1 (https=)
CN (1) CN111164105B (https=)
AR (1) AR113022A1 (https=)
AU (1) AU2018341959B2 (https=)
BR (1) BR112020003628A2 (https=)
CA (1) CA3077304C (https=)
CL (1) CL2020000705A1 (https=)
CO (1) CO2020002170A2 (https=)
CR (1) CR20200127A (https=)
DO (1) DOP2020000060A (https=)
EA (1) EA202090563A1 (https=)
EC (1) ECSP20020293A (https=)
IL (1) IL273529A (https=)
JO (1) JOP20200069A1 (https=)
MA (1) MA50654A (https=)
MX (1) MX2020003563A (https=)
MY (1) MY199876A (https=)
NZ (1) NZ762312A (https=)
PE (1) PE20201494A1 (https=)
PH (1) PH12020550340A1 (https=)
SG (1) SG11202002572YA (https=)
TW (1) TWI701260B (https=)
WO (1) WO2019067293A1 (https=)
ZA (1) ZA202001058B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2023010065A2 (en) * 2021-07-29 2023-02-02 Cephalon Llc Compositions and methods for anti-pacap antibodies
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
KR102839881B1 (ko) * 2021-11-19 2025-07-31 대한민국 방송통신기자재 성능 측정 시스템 및 그 방법
WO2024218541A1 (en) * 2023-04-20 2024-10-24 Mark Hasleton Treatment of migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486472A (en) 1990-03-17 1996-01-23 Takeda Chemical Industries, Ltd. Monoclonal antibodies to PACAP
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
CA2906737C (en) * 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US10822408B2 (en) * 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
BR112020003628A2 (pt) 2020-09-01
CO2020002170A2 (es) 2020-04-01
ZA202001058B (en) 2022-06-29
PE20201494A1 (es) 2020-12-29
CN111164105A (zh) 2020-05-15
AU2018341959A1 (en) 2020-03-05
CA3077304A1 (en) 2019-04-04
TWI701260B (zh) 2020-08-11
US10954292B2 (en) 2021-03-23
JP7221352B2 (ja) 2023-02-13
CA3077304C (en) 2023-08-01
US20200131256A1 (en) 2020-04-30
US10519225B2 (en) 2019-12-31
JOP20200069A1 (ar) 2020-04-28
JP2020535167A (ja) 2020-12-03
SG11202002572YA (en) 2020-04-29
KR20200040881A (ko) 2020-04-20
JP2022000049A (ja) 2022-01-04
CR20200127A (es) 2020-04-08
US20190100579A1 (en) 2019-04-04
ECSP20020293A (es) 2020-06-30
IL273529A (en) 2020-05-31
PH12020550340A1 (en) 2022-05-02
MY199876A (en) 2023-11-27
NZ762312A (en) 2022-11-25
EA202090563A1 (ru) 2020-06-24
AR113022A1 (es) 2020-01-15
JP6952888B2 (ja) 2021-10-27
CL2020000705A1 (es) 2020-09-11
EP3688035A1 (en) 2020-08-05
CN111164105B (zh) 2023-07-04
MX2020003563A (es) 2020-08-03
AU2018341959B2 (en) 2021-11-25
TW201920280A (zh) 2019-06-01
DOP2020000060A (es) 2020-08-15
KR102453573B1 (ko) 2022-10-12
WO2019067293A1 (en) 2019-04-04
US20210171616A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
IL272227A (en) Anti-tigit antibodies
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (en) ANTI-TIGITE ANTIBODY
MA53434A (fr) Anticorps anti-tigit
IL269405A (en) Anti-sirp alpha antibodies
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (en) ANTI-LAG-3 ANTIBODY
EP3423089A4 (en) ANTI-Tigit ANTIBODY
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
EP3883970A4 (en) ANTI-B7-H3 ANTIBODIES
EP3334757A4 (en) ANTI-Tigit ANTIBODY
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
MA50352A (fr) Anticorps multispécifiques
MA46057A (fr) Anticorps anti-ctla4
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
EP3492591A4 (en) ANTI-B7-H4 ANTIBODIES
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
EP3526247A4 (en) Anti-il1-rap antibodies
EP3399992A4 (en) SELF-NETWORKING ANTIBODIES
EP3484919A4 (en) ANTIBODIES AGAINST AMYLOID BETA
MA51134A (fr) Anticorps anti-alpha-synucléine